ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged misleading statements regarding its Iomab-B Biologics License Application during the Class Period from October 31, 2022, to August 2, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Actinium made false and/or misleading statements about the likelihood of FDA approval for its Iomab-B BLA, particularly regarding data from the Sierra Trial [5]. - It is alleged that the additional analyses provided to the FDA were unlikely to meet the necessary guidelines for approval, leading to potential refusal or rejection of the BLA [5]. - The lawsuit asserts that the misleading statements caused investors to suffer damages when the true situation became known [5]. Group 2: Participation Information - Investors who purchased Actinium securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by May 26, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in past years, including over $438 million secured in 2019 [4].